Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 595-607

  Kopkan, Libor ^a   Husková, Zuzana ^a   Sporková, Alexandra ^a   Varcabová, Šárka ^a   Honetschlägerová, Zuzana ^a   Hwang, Sung Hee ^c   Tsai, Hsing Ju ^c   Hammock, Bruce D ^c   Imig, John D ^d   Kramer, Herbert J ^e   Bürgelová, Marcela ^a   Vojtíšková, Alžběta ^a   Kujal, Petr ^a,b   Vernerová, Zdenka ^a,b   Červenka, Luděk ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

Cytochrome P450 metabolites; Endothelial nitric oxide synthase; Epoxyeicosatrienoic acids; Nitric oxide; One clip Goldblatt hypertension; Renin angiotensin system; Sodium excretion; Soluble epoxide hydrolase; Two kidney

Indexed keywords

ANGIOTENSIN II; CIS 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEX YLOXY] BENZOIC ACID; CYTOCHROME P450; DIHYDROXYICOSATRIENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENOVASCULAR HYPERTENSION; SODIUM EXCRETION; TELEMETRY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HYPERTENSION, RENOVASCULAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III;

EID: 84865607664     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000339883     Document Type: Article

References (39)

1. Ploth DW: Angiotensin-dependent renal mechanism in two-kidney, one-clip renal vascular hypertension. Am J Physiol 1983; 245:F131-F141.
2. Navar LG, Zou L, Von Thun A, Wang CT, Imig JD, Mitchell KD: Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13: 170-176.
3. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
4. Guan S, Fox K, Mitchell, Navar LG: Angiotensin and angiotensin-converting enzyme tissue levels in two-kidney, one-clip hypertensive rats. Hypertension 1992; 20: 763-767.
5. El-Dahr SS, Dipp S, Guan S, Navar LG: Renin, angiotensinogen, and kallikrein gene expression in two-kidney Goldblatt hypertensive rats. Am J Hypertens 1993; 6: 914-919.
6. Cervenka L, Wang CT, Mitchell KD, Navar LG: Proximal tubular angiotensin II levels and renal functional responses to AT 1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 1999; 33: 102-107.
7. Červenka L, Vaněčková I, Husková Z, Vaňourková Z, Erbanová M, Thumová M, Škaroupková P, Opočenský M, Malý J, Čertíková Chábová V, Tesař V, Bürgelová M, Viklický O, Teplan V, Želízko M, Kramer HJ, Navar LG: Pivotal role of AT 1A receptors in the development of two-kidney, one-clip hypertension: Study in AT 1A receptor knockout mice. J Hypertens 2008; 26: 1379-1389.
8. Walkowska A, Škaroupková P, Husková Z, Vaňourková Z, Čertíková Chábová V, Tesař V, Kramer HJ, Falck JR, Imig JD, Kompanovska-Jezierska E, Sadowski J, Červenka L: Intrarenal cytochrome P450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens 2010; 28: 582-593.
9. Sarkis A, Lopez B, Roman RJ: Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens 2004; 13: 205-214.
10. Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH: Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens 2001; 19: 983-992.
11. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tommer KB, Zeldin DC: Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010; 24: 3770-3781.
12. Imig JD: Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol 2010; 56: 329-335.
13. Sporkova A, Kopkan L, Varcabová A, Husková Z, Hwang SH, Hammock BD, Imig JD, Kramer HJ, Červenka L: Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in two-kidney, one-clip hypertensive rats. Am J Physiol 2011; 300:R1468-R1475.
14. Gao J, Bellien J, Gomez E, Henry JP, Dautreaux B, Bounoure F, Skiba M, Thuillez C, Richard V: Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. J Hypertens 2011; 29: 1128-1135.
15. Hercule HC, Schunck WH, Gross V, Seringer J, Leung FP, Weldon SM, da Costa Goncalves ACh, Huang Y, Luft FC, Gollasch M: Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009; 29: 54-60.
16. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE: Recommendations for blood pressure measurements in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals. Hypertension 2005; 45: 299-310.
17. Rakušan D, Bürgelová M, Vaněčková I, Vaňourková Z, Husková Z, Škaroupková P, Mrázová I, Opočenský M, Kramer HJ, Netuka I, Malý J, Alenina N, Bader M, Santos RAS, Červenka L: Knockout of angiotensin 1-7 receptor mas worsens the course of twokidney, one-clip Goldblatt hypertension: Roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II. Kidney Blood Press Res 2010; 33: 476-488.
18. Honetschlägerová Z, Husková Z, Vaň ourková Z, Sporková A, Kramer HJ, Hwang SH, Tsai HJ, Hammock BD, Imig JD, Červenka L, Kopkan L: Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol 2011; 589: 207-219.
19. Honetschlägerová Z, Sporková A, Kopkan L, Husková Z, Hwang SH, Hammock BD, Imig JD, Kamer HJ, Kujal P, Vernerová Z, Čertíková Chábová V, Tesař V, Červenka L: Inhibition of soluble epoxide hydrolyse improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2011; 29: 1590-1601.
20. Husková Z, Kramer HJ, Vaňourková Z, Červenka L: Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens 2006; 24: 517-527.
21. Fox J, Guan S, Hymel AA, Navar LG: Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol1992; 262:F902-F909.
22. Neckář J, Kopkan L, Husková Z, Kolář F, Papoušek F, Kramer HJ, Hwang SH, Hammock BD, Imig JD, Malý J, Netuka I, Ošťádal B, Červenka L: Inhibition of soluble epoxide hydrolase by cis -4-[4-(3-adamantan-1-ylureido) cyclohexyloxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin IIdependent hypertension. Clin Sci 2012; 122: 513-525.
23. Čertíková Chábová V, Kramer HJ, Vaněčková I, Thumová M, Škaroupková P, Tesař V, Falck JR, Imig JD, Červenka L: The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res 2007; 30: 335-346.
24. Manhiami M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, Imig JD: Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol 2009; 297:F740-F748.
25. Chin SY, Pandey KN, Shi SJ, Kobori H, Moreno C, Navar LG: Increased activity and expression of Ca 2+ -dependent NOS in renal cortex of ANG II-infused hypertensive rats. Am J Physiol 1999; 277:F797-F804.
26. Vaněčková I, Kujal P, Husková Z, Vaňourková Z, Vernerová Z, Čertíková Chábová V, Škaroupková P, Kramer HJ, Tesař V, Červenka L: Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press Res 2012; 35: 382-392.
27. Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG: An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest 1991; 88: 456-461.
28. Campbell WB, Fleming I: Epoxyeicosatrienoic acids and endothelium-dependent response. Pflugers Arch 2010; 459: 881-895.
29. Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD: 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol 1995; 268:F931-F939.
30. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD: Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15: 1244-1253.
31. Kujal P, Chabova VC, Vernerova Z, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Vanourkova Z, Huskova Z, Opocensky M, Skaroupkova P, Schejbalova S, Kramer HJ, Rakusan D, Maly J, Netuka I, Vaneckova I, Kopkan L, Cervenka L: Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: Are there blood pressure-independent effects? Clin Exp Pharmacol Physiol 2010; 37: 1159-1169.
32. Hall JE, Brands MW: The renin-angiotensin-aldosterone system: Renal mechanisms and circulatory homeostasis; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 1009-1046.
33. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C: Physiology of kidney renin. Physiol Rev 2010; 90: 607-673.
34. Williams JM, Murphy S, Burke M, Roman RJ: 20-hydroxyeicosatetraeonic acid: A new target for the treatment of hypertension. J Cardiovasc Pharmacol 2010; 56: 336-344.
35. Liu VWT, Huang PL: Cardiovascular roles of nitric oxide: A review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 2008; 77: 19-29.
36. Kopkan L, Hess A, Husková Z, Červenka L, Navar LG, Majid DSA: High-salt intake enhances superoxide activity in eNOS knockout mice leading to the development of salt sensitivity. Am J Physiol 2010; 299:F656-F663.
37. Atochin DN, Huang PL: Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflugers Arch 2010; 460: 965-974.
38. Sigmon DH, Beierwaltes WH: Renal nitric oxide and angiotensin II interaction in renovascular hypertension. Hypertension 1993; 22: 237-242.
39. Navar LG, Ichihara A, Chin SY, Imig JD: Nitric oxide-angiotensin II interactions in angiotensin II-dependent hypertension. Acta Physiol Scand 2000; 168: 139-147.